Analysts expect Envoy Medical to report Q2 2026 revenue of approximately $0.10 million and a loss per share of $0.09, with the current stock price of $0.68 trading significantly below the average analyst price target of $2.25.
The primary focus for investors is the regulatory and clinical progress of the Acclaim fully implanted cochlear implant, specifically the status of its rolling Modular PMA submission to the FDA. As a development-stage company, Envoy is currently transitioning from nominal revenue derived from legacy devices to the commercialization of its breakthrough cochlear technology. Recent updates highlighting 12-month speech perception improvements and the completion of pivotal trial enrollment provide critical context for the company’s valuation and long-term viability.